Cabozantinib and lenvatinib significantly lowered the total number of CD8+ T cells infiltrating the tumor, with a predominant distribution of these cells at the tumor interface (Supplementary Fig. S9C and S9D), as shown in bone lesions. Here, CD8A is linked to neoplasm.